Skip to main content

Table 2 Cox proportional Univariate analysis for Baseline Characteristics of Patients with or without Severe Hepatotoxicity

From: Risk factors of severe hepatotoxicity among HIV-1 infected individuals initiated on highly active antiretroviral therapy in the Northwest Region of Cameroon

Characteristics of study the population

Level

Univariate Analysis

   
  

No N (%)

Yes N (%)

OR(95%CI)

P

Age group (Years)

<30

14 (51.9)

1 3(48.1)

1

0.02

 

30–40

33 (76.7)

10 (23.3)

0.15 (0.03–0.65)

 
 

>40

25 (83.3)

5 (16.7)

0.40 (0.11–1.47)

 

Gender

Male

28 (59.6)

19 (40.4)

1

0.04

 

Female

44 (83.0)

9 (17.0)

0.26 (0.89–5.28)

 

Body Mass Index

Normal

26 (83.9)

5 (16.1)

1

0.02

 

Low

29 (61.7)

18 (38.3)

0.38 (0.04–3.35) 

 
 

Overweight

6 (85.7)

1 (14.3)

0.30 (0.11–0.78)

 
 

Obese

11 (73.3)

4 (26.7)

0.20 (0.02–1.79)

 

Level of Education

None

4 (80.0)

1 (20.0)

1

0.89

 

Primary

38 (74.5)

13 (25.5)

1.37 (0.14–13.38)

 
 

Secondary

26 (68.4)

12 (31.6)

1.84 (0.19–18.33)

 
 

Tertiary

4 (66.7)

2 (33.3)

2 (0.13–31.96)

 

Monthly income

< 50,000

51 (66.2)

26 (33.8)

1

0.01

 

>50,000

21 (91.3)

2 (8.7)

0.18 (0.04–0.86)

 

Alcohol intake

No

33 ( 75)

11 (25 )

1

0.07

 

Yes

39 (69.6 )

17 (30.4)

0.40 (0.11–1.47)

 

Cigarette or tobacco intake

No

56 (76.7)

17 (23.3)

1

0.09

 

Yes

16 (59.3)

11 (40.7)

2.26 (0.88–5.80)

 

Year of diagnosis

< 1 Year

61 (72.6)

23 (27.4)

1

0.91

 

1–3 Years

3 (75.0)

1 (25.0)

0.88 (0.09–8.94)

 
 

>3 Years

8 (66.7)

4 (33.3)

1.33 (0.36–4.83)

 

CD4 Count values in cells/μl

<200

37 (64.9)

20 (35.1)

1

0.06

 

>200

35 (81.4)

8 (18.6)

0.42 (0.161.08)

 

WHO stages

Stage 1

8 (57.1)

6 (42.9)

1

0.27

 

Stage2

32 (71.1)

13 (28.9)

0.54 (0.16–1.87)

 
 

Stage 3

30 (81.1)

7 (18.9)

0.31 (0.08–1.19)

 
 

Stage 4

2 (50.0)

2 (50.0)

1.33 (0.14–12.37)

 

Name of ARV regimen

TDF+3TC+EFV

46 (73.0)

18 (27.0)

1

0.01

 

AZT+3TC+ EFV

20 (90.9)

2 (9.1)

0.25 (0.05–1.18)

 
 

AZT+3TC+NVP

6 (42.9)

8 (57.1)

2.86 (0.90–9.04)

 
  1. 3TC: Lamivudine, AZT: Zidovudine, BMI: Body mass index, EFV: Efavirenz, NVP: Nevirapine; TDF: Tenofovir